Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATeGe
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Antibody-Based Therapeutics
01
Overview
ATeGe is an immunosuppressive agent, identified as a polyclonal antibody, investigated for its use in liver transplant recipients with pre-transplant renal dysfunction. Its purpose is to provide effective immunosuppression to prevent allograft rejection while potentially mitigating the nephrotoxicity often associated with calcineurin inhibitors, thereby aiming to improve long-term patient prognosis.
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on ATeGe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATeGe.